Remission — Reduction or Disappearance of Cancer

In oncology, remission is defined as a decrease in or disappearance of the detectable signs and symptoms of cancer. Clinicians classify remission into two primary categories: partial and complete. Partial remission denotes that the tumour burden has decreased by a predefined clinical threshold—usually at least fifty percent—or that systemic disease activity has substantially declined, though measurable disease remains present.

Complete remission indicates that all detectable signs of cancer have vanished on physical examinations, imaging scans, and laboratory evaluations. While complete remission is the ideal therapeutic outcome, it is technically distinct from a definitive cure. Microscopic clusters of dormant cancer cells, termed minimal residual disease, may persist below the detection limits of standard tests, necessitating ongoing surveillance.

Entering remission provides a clear measure of how effectively your therapy has performed. Achieving this state often brings physical relief from disease symptoms and reduces immediate treatment-related burdens. It also guides the next phase of your management plan, determining whether you transition to maintenance therapy, switch to periodic surveillance scans, or take a treatment break. Knowing your remission status allows you to collaborate closely with your clinical team to plan long-term follow-up schedules and address post-treatment survivorship needs.

Remission is confirmed through multimodal diagnostic tools. In solid tumours, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans measure tumour size against baseline images. For haematological malignancies, bone marrow biopsies and highly sensitive flow cytometry or polymerase chain reaction (PCR) tests evaluate minimal residual disease (MRD). Circulating tumour markers, such as CA-125 in ovarian cancer or prostate-specific antigen (PSA) in prostate cancer, provide additional biochemical tracking.

Remission is a standard concept across nearly all malignancies, though the term is especially prominent in haematological cancers such as acute leukaemia, chronic lymphocytic leukaemia, multiple myeloma, and non-Hodgkin lymphoma. In these blood cancers, achieving complete remission is often the primary initial goal. It is also routinely discussed in solid tumours, including advanced breast cancer, ovarian cancer, colorectal cancer, and non-small cell lung cancer, particularly when assessing response to systemic treatments.

Reaching remission frequently leads to adjustments in therapy. Depending on the cancer type, patients in complete remission may stop primary treatment and enter active surveillance, or they may begin maintenance therapy—such as targeted drugs or endocrine agents—to prevent recurrence. In leukaemia, entering remission is often a prerequisite before proceeding to high-dose consolidation therapy or an allogeneic stem cell transplant.